Share
Researchers have used gene therapy to regenerate damaged optic nerve fibres in a discovery that could help treat glaucoma, one of the world’s leading causes of blindness.
The pre-clinical study, led by Professor Keith Martin from the Centre for Eye Research Australia and University of Melbourne and Dr Richard Eva and Professor James Fawcett from the John van Geest Centre for Brain Repair at the University of Cambridge, is published today in Nature Communications.
Professor Martin says the findings bring hope of future treatments which could repair nerve damage which causes blindness in glaucoma and potentially even restore sight.
Around 300,000 Australians have glaucoma, a disease caused by progressive damage to the optic nerve, which transfer visual information from the eye to the brain.
Conventional treatments focus on reducing eye pressure to prevent optic nerve damage, but they do not work for about 15 per cent of patients and there is currently no way to repair damaged nerve cells.
About the research
The team tested whether a gene responsible for producing a protein known as protrudin could stimulate the regeneration of nerve cells and stop them from dying when they were injured.
They used a cell culture system to grow brain cells in the lab and then injured them using a laser before introducing a gene to increase the amount of protrudin in the cells, vastly increasing their ability to repair and regenerate.
Tests of eye and optic nerve cells found the protein enabled significant regeneration weeks after a crush injury to the optic nerve.
The research demonstrated almost complete protection of nerve cells from a mouse retina growing in cell culture, a technique which would usually be expected to result in extensive cell death.
New potential
Professor Martin says the results are promising. “What we’ve seen is the strongest regeneration of any technique we’ve used before,’’ he says.
“In the past it seemed impossible we would be able to regenerate the optic nerve but this research shows the potential of gene therapy to do this.’’
The international team is continuing its collaboration in Melbourne and Cambridge. Professor Martin says next steps are to explore the ability of protrudin to protect and regenerate human retinal cells.
’The research was supported in the UK by The Medical Research Council, Fight for Sight, The Bill and Melinda Gates Foundation, Cambridge Eye Trust and the National Eye Research Council.
Read the full study at Petrova, V et al. Protrudin functions from the endoplasmic reticulum to support axon regeneration in the adult CNS. Nat Comms; 5 Nov 2020; DOI: 10.1038/s41467-020-19436-y
Glaucoma Australia recently hosted a congenital glaucoma brunch at the Currumbin Wildlife Sanctuary Gold Coast and what a memorable day it was!
Australia could face a staggering $4.3 billion economic burden from glaucoma by 2025 unless the Federal Government acts now to improve patient compliance, warns Glaucoma Australia.
Leaving a gift in your Will is a spark of generosity that will continue beyond our lifetime. It allows us to invest in the research that will one day find a cure and continue to support families impacted by glaucoma.